VT-1908 · Anterior Uveitis
The unmet need
A new path for patients beyond steroid-based care.
Uveitis is a leading cause of blindness. Current treatments are often dominated by steroids, leaving patients with side effects, contraindications, or insufficient response.
VT-1908 is designed to support a differentiated uveitis treatment approach
Inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme driving immune-cell activity
Demonstrated comparable efficacy to steroids in preclinical uveitis models
Preclinical evidence
VT-1908 demonstrated an efficacy profile comparable to topical steroid treatment while showing no ocular irritation or signs of systemic toxicity in reported preclinical work.
Comparable efficacy
Comparable to steroid treatment in preclinical uveitis models.
Reduced uveitis scores
Twice-daily topical VT-1908 significantly reduced uveitis scores in preclinical studies.
Target concentration achieved
The treatment achieved the desired drug concentration in the anterior chamber.
No ocular irritation observed
No ocular irritation or signs of systemic toxicity were reported in the preclinical work.
Program outlook
Advancing toward clinical development in uveitis.
VT-1908 is being advanced with the potential to redefine treatment standards in immune-related eye disease.
Estimated U.S. addressable market
~$3B
Estimated market opportunity
View the full pipeline
